Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally.
The last earnings update was 14 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Akcea Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Akcea Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Akcea Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Akcea Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Akcea Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Akcea Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Akcea Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Akcea Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Akcea Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 21.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Paula Soteropoulos has been the Chief Executive Officer and Director of Akcea Therapeutics, Inc. since January 2015 and served as President since January 2015 until April 17, 2018. Prior to joining Akcea, Ms. Soteropoulos was a member of the executive leadership team of Moderna Therapeutics as the Cardiometabolic Business Unit General Manager and Senior Vice President of Strategic Alliances from July 2013 to December 2014, a global strategic and operating management executive with over 25 years of success at building high-performance global teams, leading complex development programs from early stage through approval and commercializing global products. Prior to Moderna, Ms. Soteropoulos served as the Vice President and General Manager of Genzyme’s Global Cardiovascular business. She was responsible for the development and commercialization of multiple therapeutics across Renal, Transplant & Oncology, Rare Disease and Cardiovascular. During her tenure at Genzyme, she was instrumental in advancing new compounds from discovery through clinical development and commercialization with significant roles driving product strategy, portfolio, program and alliance management, sales and marketing and business development. Additionally, Ms. Soteropoulos led strategic manufacturing capacity planning, supply chain development and manufacturing process development. Prior to Genzyme, she was a Bioprocess Engineering Consultant for various biopharmaceutical companies. She serves as Director at JFYNet. She has been a Director of uniQure N.V. since July 22, 2013. She serves as a Member of Advisory Board at the Tufts University Chemical and Biological Engineering Department. She is a Member of the Healthcare Business Women’s Association and serves as a Mentor. She was a honoree of Mass High Tech’s Women to Watch. She served as a Member of Supervisory Board at uniQure N.V. since July 22, 2013 until June 15, 2016. Ms. Soteropoulos earned her B.S. and M.S. in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia.
Paula's compensation has increased whilst company is loss making.
Paula's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Akcea Therapeutics management team is less than 2 years, this suggests a new team.
CEO & Director
President & Director
Chief Operating Officer
Chief Financial Officer
Vice President of Communications & Investor Relations
VP of Legal & Corporate Secretary
Chief Compliance Officer
Vice President of Human Resources
Senior VP & Global Franchise GM
Louis St. O'Dea
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Akcea Therapeutics board of directors is less than 3 years, this suggests a new board.
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.